Zepbound

Eli Lilly and Company is a global pharmaceutical leader headquartered in Indianapolis, Indiana, with a legacy spanning over 145 years. The company is widely recognized for its dominant position in the diabetes and obesity markets, particularly through its innovative incretin therapies like tirzepatide, marketed as Zepbound and Mounjaro. Lilly also maintains a significant presence in oncology, immunology, and neuroscience, recently launching Kisunla for Alzheimer's disease. With a robust R&D engine and extensive global manufacturing capabilities, the company focuses on developing first-in-class and best-in-class biologics and small molecules. Lilly is currently one of the most valuable healthcare companies in the world by market capitalization.